Neurological Disease Working Group

AfPA’s Neurological Disease Working Group is a network of policy-minded health care providers who advocate for patient-centered care.

By participating in advocacy initiatives and the development of educational resources, working group members ensure that the clinician’s perspective informs policy discussions that impact health care for people living with neurological diseases.

To learn more, or to join AfPA’s Neurological Disease Working Group, please email

TAKE ACTION: ICER’s Review on Alzheimer’s Treatment

The Institute for Clinical and Economic Review, or ICER, is reviewing a new treatment for Alzheimer’s disease. ICER’s upcoming review will examine a medication, Aducanumab, that could be the first disease modifying treatment approved to treat Alzheimer’s disease.

ICER’s reports can influence health plans’ decisions about coverage. Input from advocacy organizations, health care providers and patients is critical. Get involved here >>


White Papers & Policy Briefs




Find recent blogs here.